Skip to content

GlobalRPh Renal Dosing Masterv6.8

Clinical interpretation | Version 6.8

Find the difference.
Keep the context.

Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.

Search source differences

451 notes across 412 drug/product records.

How to interpret these notes

Generic name, brand, source or issueType of differenceAdded in v6.8

Clear filters Export all filtered notes

Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.

A difference is not always a contradiction

Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.

451 matching notes. Showing 241-256; page 16 of 29.

qualitative precaution

Mafenide acetate - SULFAMYLON for 5% topical solution

Topical solution can have qualitative renal safety implications

The historical solution source links renal dysfunction to systemic accumulation and acid-base risk without a CrCl table.

What to reconcile

Keep the warning visible. Verify current product labeling before adopting an institutional protocol.

1 source identities and dates

GlobalRPh RX List - SULFAMYLON 5% solution

GlobalRPh-hosted RX List | Source revision: Mirror prints April 2006 revision and FDA revision date December 18, 2002.
Mafenide acetate powder for SULFAMYLON 5% topical solution used in burn care; not the separate cream formulation.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.

Open / share source review Open drug and compare sources

pk evidence limit

Marstacimab-hncq - HYMPAVZI

Mild-impairment PK is not a moderate/severe renal dosing recommendation

The selected HYMPAVZI section describes mild-impairment PK and unknown lower-function effects. Its printed boundary wording also leaves a gap.

What to reconcile

Do not promote this to a universal no-adjustment badge or infer dialysis eligibility. Confirm complete labeling and the hemophilia treatment plan.

1 source identities and dates

GlobalRPh RX List - HYMPAVZI

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Subcutaneous HYMPAVZI marstacimab; renal PK statement, not rescue-bleed therapy

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.

Open / share source review Open drug and compare sources

source scope and renal guidance

Mavacamten - CAMZYOS capsules

Before use: Mavacamten - CAMZYOS capsules

PK observations are not a renal dosing ladder; the source groups overlap at 30.

What to reconcile

Review current full CAMZYOS monitoring and interaction requirements; do not select a dose from these PK rows.

1 source identities and dates

Mavacamten - CAMZYOS capsules

DailyMed / NLM exact product labeling | Source revision: 4/2025
Adult symptomatic obstructive hypertrophic cardiomyopathy. Renal pharmacokinetics only.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v6.3.

Open / share source review Open drug and compare sources

formulation dialysis scope

Meloxicam capsules (VIVLODEX)

Product-specific dialysis ceiling and non-equivalent formulations

VIVLODEX separately states a dialysis maximum while retaining its severe-renal warning, and explicitly disclaims equivalence with other oral meloxicam products. Other local meloxicam records cannot supply substitute strengths.

What to reconcile

Read the dialysis-specific dosage and overall NSAID risk together. Confirm formulation, dialysis status and toxicity monitoring rather than applying another product's milligram maximum.

1 source identities and dates

GlobalRPh RX List - Vivlodex

GlobalRPh-hosted RX List | Source revision: November 2024
VIVLODEX capsules, which the source states are not interchangeable with other oral meloxicam formulations.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.

Open / share source review Open drug and compare sources Meloxicam tablets - related, not interchangeable Meloxicam orally disintegrating tablets (QMIIZ ODT) - related, not interchangeable Meloxicam injection (XIFYRM) - related, not interchangeable

formulation separation

Meloxicam injection (XIFYRM)

IV and orally disintegrating meloxicam have different renal restrictions

The XIFYRM IV restriction is not interchangeable with the QMIIZ ODT hemodialysis dose ceiling. Route, product and volume-depletion warnings differ.

What to reconcile

Open the exact formulation. A numerical oral ceiling does not establish an acceptable IV dose in the same patient.

1 source identities and dates

GlobalRPh RX List - XIFYRM

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
XIFYRM meloxicam IV injection; not QMIIZ ODT or oral meloxicam tablets.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.5.

Open / share source review Open drug and compare sources Meloxicam orally disintegrating tablets (QMIIZ ODT) - related, not interchangeable Meloxicam tablets - related, not interchangeable

source scope and renal guidance

Memantine

Before use: Memantine

Selected IR renal target agrees; this does not validate the full dated mirror or imply equivalence to ER.

What to reconcile

Use the release-specific maintenance limit and review initial/restart titration.

2 source identities and dates

Memantine - immediate-release tablets

DailyMed / NLM exact product labeling | Source revision: 09/2021
Adults with moderate-to-severe Alzheimer-type dementia; exact release formulation.

Read this stored source

GlobalRPh RX List - NAMENDA

GlobalRPh-hosted RX List | Source revision: November 2018
Adult immediate-release memantine; not NAMENDA XR.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.

Open / share source review Open drug and compare sources

formulation scope

Memantine - NAMENDA XR capsules

NAMENDA XR: renal maintenance and release-form conversion

Severe-impairment maintenance and switching instructions specify both the prior immediate-release regimen and the XR product.

What to reconcile

Confirm Cockcroft-Gault clearance, release form and the established dose; avoid milligram-for-milligram substitution.

1 source identities and dates

GlobalRPh RX List - NAMENDA XR

GlobalRPh-hosted RX List | Source revision: RX page prints November 2019.
Memantine - NAMENDA XR capsules; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources Memantine - related, not interchangeable Memantine ER / donepezil - NAMZARIC capsules - related, not interchangeable

source scope and renal guidance

Memantine - NAMENDA XR capsules

Before use: Memantine - NAMENDA XR capsules

The same severe-renal CrCl band gives different formulation-specific limits: IR 5 mg twice daily versus ER 14 mg once daily.

What to reconcile

Confirm IR, ER or fixed combination; keep the maintenance limit separate from titration and restart instructions.

1 source identities and dates

Memantine - extended-release capsules

DailyMed / NLM exact product labeling | Source revision: 4/2025
Adults with moderate-to-severe Alzheimer-type dementia; exact release formulation.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.

Open / share source review Open drug and compare sources

formulation scope

Memantine ER / donepezil - NAMZARIC capsules

NAMZARIC: both established ingredients determine the pathway

Starting with established donepezil alone differs from switching an established memantine/donepezil regimen.

What to reconcile

Confirm both ingredients, stabilization and the severe-renal pathway before selecting the capsule strength.

1 source identities and dates

GlobalRPh RX List - NAMZARIC

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Memantine ER / donepezil - NAMZARIC capsules; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources Memantine - related, not interchangeable Memantine - NAMENDA XR capsules - related, not interchangeable

dose table scope

Mercaptopurine - PURIXAN oral suspension

PURIXAN: dose and interval options are not automatically cumulative

The renal sections describe a low starting dose and an interval alternative in different passages.

What to reconcile

Choose an oncology-protocol-based approach rather than applying both reductions automatically.

1 source identities and dates

GlobalRPh RX List - PURIXAN

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Mercaptopurine - PURIXAN oral suspension; selected renal passages, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.

Open / share source review Open drug and compare sources

ambiguous threshold

Meropenem / vaborbactam (Vabomere)

Renal-band endpoints differ between the label mirror and UCSF

Both tables use indexed eGFR, but the label assigns exactly 50 to its full-dose band, whereas UCSF prints >50 and 30-50. UCSF also prints overlapping bands at exactly 30. The dialysis and indication scopes are separately stated.

What to reconcile

Do not silently round an estimate, substitute unindexed CrCl, average doses, or combine one source's band with another interval. Clarify boundary cases with the applicable label and institutional antimicrobial team.

2 source identities and dates

GlobalRPh RX List - Vabomere

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult IV VABOMERE for complicated urinary tract infection, including pyelonephritis; amounts are combined meropenem plus vaborbactam.

Read this stored source

UCSF: meropenem/vaborbactam renal and dialysis tables

UCSF Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval.
UCSF adult institutional all-indications table; not a replacement for exact labeled indication and boundaries.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.

Open / share source review Open drug and compare sources

guideline vs label scope

Metformin

First decide: new initiation or continued therapy

The joint ADA/KDIGO 2022 consensus supports selected CKD use with a lower daily dose at eGFR 30-44. The U.S. label separately discourages initiation between eGFR 30 and 45 and requires benefit-risk reassessment for continued therapy below 45.

What to reconcile

Do not interpret a continuation strategy as automatic authorization for a new start. Reconcile label, guideline, acute illness and monitoring; document the plan, including when therapy should be held or reassessed.

2 source identities and dates

Metformin hydrochloride immediate-release tablets

NIH/NLM DailyMed - U.S. prescribing information | Source revision:
Adults; oral immediate-release tablets, not extended-release or fixed combinations.

Read this stored source

ADA/KDIGO 2022 - metformin in CKD

American Diabetes Association / KDIGO | Source revision: 2022 ADA/KDIGO consensus, Diabetes Care 45:3075-3090
Adults with type 2 diabetes and CKD; 2022 joint consensus, not asserted to be the latest 2026 guideline.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.4.

Open / share source review Open drug and compare sources

international label difference

Methenamine hippurate (UREX)

U.S.-source renal restriction differs from UK HIPREX wording

UREX describes renal insufficiency as a contraindication without a number. UK HIPREX prescribing information permits its stated 10-50 mL/min categories while contraindicating severe failure below 10.

What to reconcile

Do not import the UK threshold into a U.S. regimen without explicit product and jurisdiction review. Reconcile indication, urinary acidity, interactions and renal method; international labeling is not independent U.S. approval.

2 source identities and dates

GlobalRPh RX List - Urex

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Oral methenamine hippurate UREX source; not methenamine mandelate.

Read this stored source

Viatris UK: HIPREX renal wording (international comparison)

Viatris UK manufacturer prescribing information | Source revision: July 2025
International comparator for oral methenamine hippurate; NOT U.S. prescribing authorization.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.6.

Open / share source review Open drug and compare sources Methenamine hippurate tablets (Hiprex) - related, not interchangeable

dose table scope

Methylene blue - PROVAYBLUE

PROVAYBLUE: renal impairment limits the selected course to one dose

The selected renal pathway calls for a single infusion and consideration of alternatives when response is inadequate. It does not authorize the general repeat-dose pathway.

What to reconcile

Retain acquired-methemoglobinemia scope and serotonergic-drug warnings. Do not extrapolate to vasoplegia.

1 source identities and dates

GlobalRPh RX List - PROVAYBLUE

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Methylene blue - PROVAYBLUE; selected renal source sections only, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.

Open / share source review Open drug and compare sources

dose table scope

Methylene blue - PROVAYBLUE

PROVAYBLUE: renal single-dose instruction limits general repeat dosing

For the selected impaired-renal band, persistent methemoglobinemia prompts alternative interventions rather than the usual repeat-dose pathway.

What to reconcile

Do not reapply the general repeat-dose rule without the renal qualification.

1 source identities and dates

GlobalRPh RX List - PROVAYBLUE

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Methylene blue - PROVAYBLUE renal repeat-dose limit; selected renal passages, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.

Open / share source review Open drug and compare sources

monitoring scope

Metyrosine - DEMSER

DEMSER: crystalluria prevention requires individualized fluid assessment

The source discusses hydration and crystalluria, but a source fluid target cannot automatically be imposed in fluid-restricted kidney disease.

What to reconcile

Individualize fluid planning and monitor crystalluria/renal status; use the source response to persistent crystalluria without inventing a renal dose.

1 source identities and dates

GlobalRPh RX List - DEMSER

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Metyrosine - DEMSER; selected renal source sections only, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.

Open / share source review Open drug and compare sources

What is not established by this directory

Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.

See source and A-Z review status Home / all drugs